Padagis, a US-based pharmaceutical company, announced on Friday the launch of Brinzolamide Ophthalmic Suspension with Competitive Generic Therapy (CGT) exclusivity (generic equivalent to the Reference Listed Drug Azopt(R) Ophthalmic Suspension).

Azopt(R) Ophthalmic Suspension is indicated to decrease elevated intraocular pressure (IOP) in adult patients with ocular hypertension or open-angle glaucoma, as monotherapy in patients unresponsive to betablockers or in patients in whom beta-blockers are contraindicated, or as adjunctive therapy to betablockers.

Annual market sales for Azopt(R) were approximately USD74 million in the 12 months ended August 2023 as measured by IQVIA.

Padagis president, Pamela Hoffman, stated, 'This launch and its accompanying CGT exclusivity demonstrates the ability of the Padagis team to bring complex generic products to the markets that need them. The Padagis team continues to leverage our unique and specialised technical and commercial capabilities to deliver important products to our customers and patients.'